# Predictive Value of Minimal Residual Disease for Postoperative Recurrence and Adjuvant PD-1 Inhibitor in HCC

> **NCT07350824** · NA · NOT_YET_RECRUITING · sponsor: **Tongji Hospital** · enrollment: 276 (estimated)

## Conditions studied

- HCC
- Minimal Residual Disease
- Recurrence

## Interventions

- **DRUG:** Adjuvant PD-1 inhibitors
- **OTHER:** Active monitoring

## Key facts

- **NCT ID:** NCT07350824
- **Lead sponsor:** Tongji Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12-31
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 276 (ESTIMATED)
- **Last updated:** 2026-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07350824

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07350824, "Predictive Value of Minimal Residual Disease for Postoperative Recurrence and Adjuvant PD-1 Inhibitor in HCC". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07350824. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*